Towards protein-based viral mimetics for cancer therapies

Ugutz Unzueta; María Virtudes Céspedes; Esther Vázquez; Neus Ferrer-Miralles; Ramón Mangues; Antonio Villaverde

doi:https://doi.org/10.1016/j.tibtech.2015.02.007

Towards protein-based viral mimetics for cancer therapies

Ugutz Unzueta, María Virtudes Céspedes, Esther Vázquez, Neus Ferrer-Miralles, Ramón Mangues, Antonio Villaverde

Research output: Contribution to journal › Review article › Research › peer-review

61 Citations (Scopus)

Abstract

© 2015 Elsevier Ltd. High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or 'artificial viruses'. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting 'smart' functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug-protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs.

Original language	English
Pages (from-to)	253-258
Journal	Trends in Biotechnology
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.tibtech.2015.02.007
Publication status	Published - 1 May 2015

Keywords

Biomaterials
Biomimetics
Drug delivery
Protein engineering
Protein nanoparticles
Targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1016/j.tibtech.2015.02.007

https://ddd.uab.cat/record/174085

Cite this

@article{0ccbd7bb6c284c7eb8fcfb9374fbf0a4,

title = "Towards protein-based viral mimetics for cancer therapies",

abstract = "{\textcopyright} 2015 Elsevier Ltd. High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or 'artificial viruses'. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting 'smart' functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug-protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs.",

keywords = "Biomaterials, Biomimetics, Drug delivery, Protein engineering, Protein nanoparticles, Targeted therapy",

author = "Ugutz Unzueta and C{\'e}spedes, {Mar{\'i}a Virtudes} and Esther V{\'a}zquez and Neus Ferrer-Miralles and Ram{\'o}n Mangues and Antonio Villaverde",

year = "2015",

month = may,

day = "1",

doi = "https://doi.org/10.1016/j.tibtech.2015.02.007",

language = "English",

volume = "33",

pages = "253--258",

journal = "Trends in Biotechnology",

issn = "0167-7799",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Towards protein-based viral mimetics for cancer therapies

AU - Unzueta, Ugutz

AU - Céspedes, María Virtudes

AU - Vázquez, Esther

AU - Ferrer-Miralles, Neus

AU - Mangues, Ramón

AU - Villaverde, Antonio

PY - 2015/5/1

Y1 - 2015/5/1

N2 - © 2015 Elsevier Ltd. High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or 'artificial viruses'. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting 'smart' functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug-protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs.

AB - © 2015 Elsevier Ltd. High resistance and recurrence rates, together with elevated drug clearance, compel the use of maximum-tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or 'artificial viruses'. Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing virus-like molecular vehicles. By exhibiting 'smart' functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug-protein conjugates already in the clinic in ensuring efficient delivery of passenger antitumor drugs.

KW - Biomaterials

KW - Biomimetics

KW - Drug delivery

KW - Protein engineering

KW - Protein nanoparticles

KW - Targeted therapy

U2 - https://doi.org/10.1016/j.tibtech.2015.02.007

DO - https://doi.org/10.1016/j.tibtech.2015.02.007

M3 - Review article

SN - 0167-7799

VL - 33

SP - 253

EP - 258

JO - Trends in Biotechnology

JF - Trends in Biotechnology

IS - 5

ER -

Towards protein-based viral mimetics for cancer therapies

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this